Trial Profile
Multicentre, open label, uncontrolled, pilot, phase II study of oral ITF2357 in subjects with acute myeloid leukemia refractory/resistant and/or not suitable for any alternative therapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 May 2011
Price :
$35
*
At a glance
- Drugs Givinostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Italfarmaco
- 25 May 2011 New trial record